HEMISPHERX BIOPHARMA INC (HEB) Stock Price, Quote, News and Overview
NYSEARCA:HEB - NYSE Arca -
HEB Quote, Performance and Key Statistics
1.8
-0.01 (-0.55%)
The current stock price of HEB is 1.8 null. In the past month the price decreased by -19.28%. In the past year, price decreased by -85.12%.
About HEB
Company Profile
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection and the experimental therapeutics Ampligen and Oragens. Alferon N Injection is approved for a category of STD infection, and Ampligen and Oragens represent a large portfolio experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technologies address.
Company Info
HEMISPHERX BIOPHARMA INC
2117 SW HIGHWAY 484
OCALA FL 34473
CEO: Thomas K. Equels
Phone: 215-988-0080
HEMISPHERX BIOPHARMA INC / HEB FAQ
What is the stock price of HEMISPHERX BIOPHARMA INC today?
The current stock price of HEB is 1.8 null. The price decreased by -0.55% in the last trading session.
What is the ticker symbol for HEMISPHERX BIOPHARMA INC stock?
The exchange symbol of HEMISPHERX BIOPHARMA INC is HEB and it is listed on the NYSE Arca exchange.
On which exchange is HEB stock listed?
HEB stock is listed on the NYSE Arca exchange.
What is HEMISPHERX BIOPHARMA INC worth?
HEMISPHERX BIOPHARMA INC (HEB) has a market capitalization of 4.40M null. This makes HEB a Nano Cap stock.
What are the support and resistance levels for HEMISPHERX BIOPHARMA INC (HEB) stock?
HEMISPHERX BIOPHARMA INC (HEB) has a resistance level at 1.93. Check the full technical report for a detailed analysis of HEB support and resistance levels.
Should I buy HEMISPHERX BIOPHARMA INC (HEB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HEB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HEB, evaluating the profitability, health, valuation and growth aspects
- HEMISPHERX BIOPHARMA INC (HEB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HEMISPHERX BIOPHARMA INC (HEB) Sales and EPS estimates to see what analysts future expectations are.
- HEMISPHERX BIOPHARMA INC (HEB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HEMISPHERX BIOPHARMA INC (HEB) Insider and Institutional Ownership to learn about the owners and their transactions.
- HEMISPHERX BIOPHARMA INC (HEB) Stock Chart to make your own analysis
- HEMISPHERX BIOPHARMA INC (HEB) Latest news and press-releases to stay up to date.
Does HEMISPHERX BIOPHARMA INC (HEB) stock pay dividends?
HEB does not pay a dividend.
What is the Price/Earnings (PE) ratio of HEMISPHERX BIOPHARMA INC (HEB)?
HEMISPHERX BIOPHARMA INC (HEB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.54).
HEB Technical Analysis
HEB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HEB. HEB has a bad profitability rating. Also its financial health evaluation is rather negative.
HEB Financial Highlights
Over the last trailing twelve months HEB reported a non-GAAP Earnings per Share(EPS) of -5.540000000000001. The EPS decreased by -2418.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -3284.04% | ||
| ROA | -73.02% | ||
| ROE | -153.97% | ||
| Debt/Equity | 0.37 |
HEB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 60% to HEB. The Buy consensus is the average rating of analysts ratings from 1 analysts.